Metabonomic Evaluation of ZHENG Differentiation and Treatment by Fuzhenghuayu Tablet in Hepatitis-B-Caused Cirrhosis
Figure 4
Five maps revealed the therapeutic effect of FZHY tablet for hepatitis-B-caused cirrhosis (HBC) and four TCM ZHENG types, respectively: spleen deficiency with dampness encumbrance syndrome (SDDES), liver-gallbladder dampness-heat syndrome (LGDHS), liver-kidney yin deficiency syndrome (LKYDS), and blood stasis syndrome (BSS), by the changing trend of significantly differential metabolites. CG is short for control group; preoral in each group stands for information before intervention of FZHY tablet; 12th week means effects after 12-week intervention by FZHY tablet; 24th week means effects after 24-week intervention. The x-axis represented the changed metabolites, and the y-axis was average rank in Mann-Whitney U-test, representing the contents of metabolites.
